Drug Profile
Bifikafusp alfa - Philogen
Alternative Names: Anti-EDB-IL2 antibody conjugate; Anti-EDB-interleukin-2 antibody conjugate; Darleukin; Immunocytokine therapy; L19 interleukin-2 fusion-protein; L19-IL-2; L19-IL2 fusion proteinLatest Information Update: 18 Oct 2023
Price :
$50
*
At a glance
- Originator Philogen
- Developer Bayer Schering Pharma; Maastricht Radiation Oncology; Philogen
- Class Antineoplastics; Cytokines; Immunotherapies; Monoclonal antibodies; Recombinant fusion proteins
- Mechanism of Action Interleukin-2 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-small cell lung cancer
- Phase I/II Diffuse large B cell lymphoma
- No development reported Malignant melanoma; Renal cell carcinoma; Solid tumours
- Discontinued Atherosclerosis; Head and neck cancer; Pancreatic cancer
Most Recent Events
- 10 Oct 2023 Philogen terminates a phase-I/II trial in Diffuse large B cell lymphoma (Second-line therapy or greater, Combination therapy) in Germany (IV) (NCT02957019)
- 01 Jun 2023 Philogen enters into a clinical trial collaboration and supply agreement with MSD for L19IL2
- 04 Apr 2019 Phase-II clinical trials in Non-small cell lung cancer (Metastatic disease) in United Kingdom (IV) (NCT03705403)